

--21. A polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) with glucosyltransferase activity, consisting essentially of approximately the first 1020 N-terminal amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) according to SEQ ID NO:1, or a portion thereof having glucosyltransferase activity.

22. A compound comprising a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) according to SEQ ID NO:1, or a portion thereof, the compound having (i) a glucosyltransferase activity domain, and (ii) a target cell specific binding domain which permits the compound to bind to a target cell.

23. A compound comprising a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) as defined by SEQ ID NO:1, or a portion thereof, the compound having (i) a glucosyltransferase activity domain, (ii) a target cell specific binding domain, which domain causes the compound to bind to a target cell, and (iii) a translocation domain for translocating a catalytic domain of *Clostridium sordellii* lethal Toxin (LT) from the exterior of a cell into the interior of said cell.

24. A compound according to claim 23, wherein the translocation domain consists essentially of approximately the N-terminal amino acids 1021-1700 of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT).

25. A compound according to one of claims 22 to 24, wherein the target cell specific binding domain is an antibody or an antigen binding fragment thereof.

*duplicate*

26. A composition comprising a compound according to one of claims 22 to 24 and a pharmaceutically acceptable adjuvant or carrier.

27. A composition comprising a compound according to claim 25 and a pharmaceutically acceptable adjuvant or carrier.

28. A method of manufacturing a composition, said method comprising the steps of bringing together a compound according to one of claims 22 to 24 and a pharmaceutically acceptable adjuvant or carrier.

29. A method of manufacturing a composition, said method comprising the steps of bringing together a compound according to claim 25 and a pharmaceutically acceptable adjuvant or carrier.--